Getasorb: indications and contraindications for pancreatitis

After surgery for pancreatitis, the doctor may prescribe the use of the drug Getasorb. This medicine is a clear or slightly yellowish solution for infusion.

The active substance of the drug is hydroxyethyl starch Na + and Cl-, auxiliary components include sodium chloride and water.

The drug has a plasma-substituting effect if the patient has hypovolemia and shock as a result of surgery, injury, burn, the development of an infectious disease, and blood circulation disorders in the vessels.

How does the drug

The drug with plasma-substituting action consists of hydroxyethylated starch. This substance is a high-molecular compound, which consists of polymerized glucose residues. These elements are obtained from natural polysaccharides; ripe potato and corn starch is used as a source.

After the introduction of the solution into the vein, rapid hydrolization of amylopectin occurs, the substance is in the bloodstream for 20 minutes. To increase the stability and increase the duration of the drug, hydroxyethylation is used.

Pentakrahmal improves the rheological properties of blood by reducing the level of hematocrit, reducing plasma viscosity, reducing the aggregation of red blood cells, and also restores impaired microcirculation.

When pentacramide is injected intravenously, the active substance is split by the action of intensive metabolism to the formation of low molecular weight fragments. Metabolism is rapidly excreted through the kidneys.

Most of the drug leaves the body through the urine and through the intestines on the first day, and the remaining substances - during the week.

Indications and contraindications of the drug

In attacks of acute pancreatitis, the space behind the peritoneum is filled with fluid, which can lead to hypovolemia. The drug is used if there is acute blood loss and a solution of crystalloids is not enough.

Treatment GetaSorb 10% and 6% is contraindicated in case of hypersensitivity to starch, intracranial hypertension, arterial hypertension, intracranial hemorrhage, severe heart failure, impaired kidney function, severe liver failure, cardiogenic pulmonary edema.

Also, the use of the drug is not allowed for hyperhydration, hypervolemia, dehydration, pronounced bleeding disorders, hyperchloremia, hypernatremia, hypokalemia, hemodialysis, children under 18 years of age.

  1. Drug treatment is prohibited if an open operation on the heart has been performed and the person is in critical condition.
  2. Caution should be exercised in the presence of compensated chronic insufficiency, chronic liver disease, von Willebrand disease, hemorrhagic diathesis, hypofibrinogenemia.
  3. During pregnancy, the drug can be used only as a last resort if other therapies do not help, and the benefits to the mother are much higher than the potential risk to the growing fetus. During lactation, breastfeeding should be abandoned so as not to harm the baby.

Instructions for use of the drug

Before starting therapy, you should familiarize yourself with the operating manual. The drug is effective only at the initial stage of blood volume compensation, therefore, it is administered intravenously using a drip only on the first day after blood loss.

Therapy is carried out under strict medical supervision. Immediately after receiving a positive rate, the infusion is stopped.

The prescribed daily dosage and speed of the solution should be strictly observed. First, Geta-Sorb is slowly injected so that you can follow the changes and the patient's condition. If possible anaphylactoid reactions occur, treatment immediately stops.

The doctor prescribes the dosage individually, focusing on the patient's condition, the amount of lost blood, hematocrit and hemoglobin.

  • When using a 6% solution, the rate of infusion of the drug should not exceed 20 ml per hour per kilogram of patient weight.
  • If 10% medication is used, the maximum infusion rate may be 20 ml per hour.
  • For older people, the dose should be carefully chosen, otherwise the patient may develop heart failure.

Presence of side effects

An adverse reaction can occur if no additional blood components are injected. Improper dilution can negatively affect blood clotting.

In rare cases, hypersensitivity is possible, which does not depend on the dosage administered. The hematocrit often decreases and dilutional hypoproteinemia develops.

Exceeding the injected dose leads to a violation of blood clotting, an increase in bleeding time. Rarely rashes appear on the skin, while the face and neck become red, shock, heart and respiratory failure develops.

  1. Plasma α-amylase activity sometimes increases, but this is not a signal of pancreatic malfunction. Infrequently, with repeated administration of the solution, itching develops throughout the day.
  2. If the drug is injected in a large volume and too quickly, acute left ventricular failure and pulmonary edema develop, and blood clotting is disturbed.
  3. When it becomes difficult for the patient to breathe, he feels soreness in the lumbar region, chills, cyanosis, the blood circulation and the respiratory process are disturbed, and the treatment immediately stops.

The active substance of the drug helps to increase the nephrotoxicity of aminoglycoside antibiotics. At the same time taking anticoagulants increases the duration of bleeding. Mixing medication with other drugs is not allowed.

Apply the solution can only be prescribed by the attending physician. The shelf life of 6% solution is 4 years, 10% - 5 years. Unopened vial stored at temperatures up to 25 degrees away from children. Liquid freezing should not be allowed.

The price of the drug is low and amounts to only 130 rubles per bottle of 500 ml. It is possible to get solution for infusions according to the prescription in a drugstore. The more expensive counterparts include drugs Voluven, Refortan, HyperCHPP, Infuzol HES, Stabizol, Hemohesus, Volekam.

Information about the treatment of pancreatitis is provided in the video in this article.

Watch the video: APD Pancreatic Pseudocyst Procedure (October 2019).